As usual well done Abdm.!
An excellent response.
Seems its just a matter of time before ADAPT tissue is used for pelvic floor operations but hernia repairs could be approved earlier. Im sure AHZ management are working on bringing these uses on line but given all the work in fast tracking cadiocel successfully to market and the chance of also expanding its use in valve repair, vascular applications etc etc they have just had to set priorities with their time at this stage.
The ADAPT tissue it seems is the best solution across the board its only a matter of time and money in expanding the market and they are already off to a marvellous start in achieving that.
Fox
EACTS 2014, page-48
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.00 | $18.00 | $2.394K | 133 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 282 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.05 | 428 | 3 |
View Market Depth
| Last trade - 09.59am 15/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |